Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy drug candidate is active in adults, leading analysts to predict the molecule “could re-imagine the … therapeutic landscape” if the biotech replicates the data in children.
Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy drug candidate is active in adults, leading analysts to predict the molecule “could re-imagine the … therapeutic landscape” if the biotech replicates the data in children.